152 related articles for article (PubMed ID: 20617363)
1. Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs.
Penel N; Adenis A; Clisant S; Bonneterre J
Invest New Drugs; 2011 Dec; 29(6):1414-9. PubMed ID: 20617363
[TBL] [Abstract][Full Text] [Related]
2. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
3. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
Colin P; Micallef S; Delattre M; Mancini P; Parent E
Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
[TBL] [Abstract][Full Text] [Related]
4. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
[TBL] [Abstract][Full Text] [Related]
5. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Potter DM
Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
[TBL] [Abstract][Full Text] [Related]
6. A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity.
Seymour L; Eisenhauer E
Cancer Chemother Pharmacol; 2001; 47(1):2-10. PubMed ID: 11221956
[TBL] [Abstract][Full Text] [Related]
7. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
[TBL] [Abstract][Full Text] [Related]
8. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
van Brummelen EM; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):235-42. PubMed ID: 26960536
[TBL] [Abstract][Full Text] [Related]
9. Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience.
Wong HH; Barton C; Acton G; McLeod R; Halford S
Eur J Cancer; 2016 Oct; 66():9-16. PubMed ID: 27514008
[TBL] [Abstract][Full Text] [Related]
10. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
Wages NA; Tait C
J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
[TBL] [Abstract][Full Text] [Related]
11. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.
Lee SM; Backenroth D; Cheung YK; Hershman DL; Vulih D; Anderson B; Ivy P; Minasian L
J Clin Oncol; 2016 Apr; 34(12):1395-401. PubMed ID: 26926682
[TBL] [Abstract][Full Text] [Related]
12. Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.
Shimomura A; Kondo S; Kobayashi N; Iwasa S; Kitano S; Tamura K; Fujiwara Y; Yamamoto N
Int J Clin Oncol; 2017 Aug; 22(4):780-785. PubMed ID: 28293794
[TBL] [Abstract][Full Text] [Related]
13. A Bayesian approach to dose-finding studies for cancer therapies: incorporating later cycles of therapy.
Sinclair K; Whitehead A
Stat Med; 2014 Jul; 33(15):2665-80. PubMed ID: 24590816
[TBL] [Abstract][Full Text] [Related]
14. Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.
Paoletti X; Le Tourneau C; Verweij J; Siu LL; Seymour L; Postel-Vinay S; Collette L; Rizzo E; Ivy P; Olmos D; Massard C; Lacombe D; Kaye SB; Soria JC
Eur J Cancer; 2014 Aug; 50(12):2050-6. PubMed ID: 24928189
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.
Le Tourneau C; Razak AR; Gan HK; Pop S; Diéras V; Tresca P; Paoletti X
Eur J Cancer; 2011 Jul; 47(10):1468-75. PubMed ID: 21482105
[TBL] [Abstract][Full Text] [Related]
16. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
17. Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology.
Frankel PH; Chung V; Xing Y; Longmate J; Groshen S; Newman EM
Curr Probl Cancer; 2020 Dec; 44(6):100583. PubMed ID: 32446637
[TBL] [Abstract][Full Text] [Related]
18. Adaptive dose-finding studies: a review of model-guided phase I clinical trials.
Iasonos A; O'Quigley J
J Clin Oncol; 2014 Aug; 32(23):2505-11. PubMed ID: 24982451
[TBL] [Abstract][Full Text] [Related]
19. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
[TBL] [Abstract][Full Text] [Related]
20. The role of age on dose-limiting toxicities in phase I dose-escalation trials.
Schwandt A; Harris PJ; Hunsberger S; Deleporte A; Smith GL; Vulih D; Anderson BD; Ivy SP
Clin Cancer Res; 2014 Sep; 20(18):4768-75. PubMed ID: 25028396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
